European pharmaceutical stocks rose broadly in line with their global counterparts after healthcare stocks in Hong Kong and New York markets rose collectively overnight. Positive signals for the sector include the prospect of a resolution to Bayer’s ongoing glyphosate litigation in the U.S.; UBS’s analysts noted that significant progress could be made in 2026, which would substantially improve the company’s fundamental outlook.Jefferies analysts wrote that a potential merger between Bayer’s Consumer Health division and Haleon would further boost the German pharmaceutical company. UBS. noted that Novartis is poised to benefit from trial data in the first quarter of 2026, following a rating upgrade from Barclays.Bayer shares rose 1.2%, Novartis shares rose 1.5%, and Sandoz Group shares rose 2.6%.